Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume

Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 2,100,000 shares of BCLI short. Learn More on Brainstorm Cell Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCLI shares currently have a short interest ratio of 2.0. Learn More on Brainstorm Cell Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Brainstorm Cell Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Brainstorm Cell Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,100,000 shares, an increase of 5.5% from the previous total of 1,990,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Brainstorm Cell Therapeutics: Surrozen, Inc. (2.15%), Pluri Inc. (0.97%), Achilles Therapeutics plc (0.06%), SAB Biotherapeutics, Inc. (0.30%), Estrella Immunopharma, Inc. (0.12%), MiNK Therapeutics, Inc. (0.88%), Quince Therapeutics, Inc. (6.58%), Cyclo Therapeutics, Inc. (0.35%), OKYO Pharma Limited (0.43%), Dyadic International, Inc. (0.96%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is April, 30 2024.